Tumor Necrosis Factor-α Inhibition Before and After Rituximab Treatment in Juvenile Idiopathic Arthritis: What Shall We Expect? A Pilot Study

Q2 Medicine

The Journal of rheumatology. Supplement Pub Date : 2022-03-15 DOI:10.3899/jrheum.211039

A. Marino, F. Orsini, F. Pregnolato, R. Cimaz

引用次数: 0

Abstract

Rituximab (RTX), a chimeric monoclonal antibody against B cell antigen CD20, has been used in patients with recalcitrant juvenile idiopathic arthritis ( JIA) with some efficacy.1,2 The resetting of peripheral B cells promoted by RTX represents quite an interesting option in autoimmune diseases such as JIA, not only for the immediate effect but also for the possible use of other therapies that might be necessary to achieve disease control.

查看原文本刊更多论文

利妥昔单抗治疗青少年特发性关节炎前后肿瘤坏死因子-α抑制:我们应该期待什么?一项初步研究

Rituximab (RTX)是一种抗B细胞抗原CD20的嵌合单克隆抗体，用于治疗顽固性幼年特发性关节炎(JIA)有一定疗效。1,2 RTX促进外周B细胞的重置在JIA等自身免疫性疾病中是一个非常有趣的选择，不仅因为其即时效果，而且还可能使用其他治疗方法来实现疾病控制。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

The Journal of rheumatology. Supplement Medicine-Medicine (all)

自引率

0.00%

发文量

期刊介绍： The Journal of Rheumatology is a monthly international serial edited by Duncan A. Gordon, The Journal features research articles on clinical subjects from scientists working in rheumatology and related fields, as well as proceedings of meetings as supplements to regular issues. Highlights of our 36 years serving Rheumatology include: groundbreaking and provocative editorials such as "Inverting the Pyramid," renowned Pediatric Rheumatology, proceedings of OMERACT and the Canadian Rheumatology Association, Cochrane Musculoskeletal Reviews, and supplements on emerging therapies.